Related Experiment Video
Updated: Mar 6, 2026
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure
Greg Goldblatt1, Lucia Cilenti2, Jason O Matos3
1Biomedical Sciences Graduate Program, University of Central Florida, Orlando, FL, USA.
Abstract:
Amyloid β (Aβ) peptide plays a major role in Alzheimer's disease (AD) and occurs in multiple forms, including pyroglutamylated Aβ (AβpE). Identification and characterization of the most cytotoxic Aβ species is necessary for advancement in AD diagnostics and therapeutics. While in brain tissue multiple Aβ species act in combination, structure/toxicity studies and immunotherapy trials have been focused on individual forms of Aβ. As a result, the molecular composition and the structural features of "toxic Aβ oligomers" have remained unresolved. Here, we have used a novel approach, hydration from gas phase coupled with isotope-edited Fourier transform infrared (FTIR) spectroscopy, to identify the prefibrillar assemblies formed by Aβ and AβpE and to resolve the structures of both peptides in combination. The peptides form unusual β-sheet oligomers stabilized by intramolecular H-bonding as opposed to intermolecular H-bonding in the fibrils. Time-dependent morphological changes in peptide assemblies have been visualized by atomic force microscopy. Aβ/AβpE hetero-oligomers exert unsurpassed cytotoxic effect on PC12 cells as compared to oligomers of individual peptides or fibrils. These findings lead to a novel concept that Aβ/AβpE hetero-oligomers, not just Aβ or AβpE oligomers, constitute the main neurotoxic conformation. The hetero-oligomers thus present a new biomarker that may be targeted for development of more efficient diagnostic and immunotherapeutic strategies to combat AD.
Insights
Novel research reveals that amyloid beta (Aβ) and pyroglutamylated Aβ (AβpE) hetero-oligomers are the primary neurotoxic species in Alzheimer's disease (AD), offering new diagnostic and therapeutic targets.
Area of Science:
- Neuroscience
- Biochemistry
- Structural Biology
Background:
- Alzheimer's disease (AD) is linked to amyloid beta (Aβ) peptides, including pyroglutamylated Aβ (AβpE).
- Current AD research often focuses on individual Aβ forms, leaving the structure and toxicity of combined species unresolved.
- Identifying the most cytotoxic Aβ species is crucial for advancing AD diagnostics and therapeutics.
Purpose of the Study:
- To characterize the prefibrillar assemblies of Aβ and AβpE, both individually and in combination.
- To resolve the structural features and cytotoxic effects of different Aβ/AβpE assemblies.
- To identify novel biomarkers for AD diagnosis and immunotherapy.
Main Methods:
- Utilized hydration from gas phase coupled with isotope-edited Fourier transform infrared (FTIR) spectroscopy.
- Employed atomic force microscopy (AFM) to visualize time-dependent morphological changes in peptide assemblies.
- Assessed the cytotoxicity of different Aβ species on PC12 cells.
Main Results:
- Identified unusual β-sheet oligomers of Aβ/AβpE stabilized by intramolecular H-bonding.
- Observed that Aβ/AβpE hetero-oligomers exhibit significantly higher cytotoxicity compared to individual peptide oligomers or fibrils.
- Visualized distinct morphological changes in peptide assemblies over time using AFM.
Conclusions:
- Aβ/AβpE hetero-oligomers represent the principal neurotoxic conformation in Alzheimer's disease.
- These hetero-oligomers serve as a promising new biomarker for AD.
- Targeting Aβ/AβpE hetero-oligomers could lead to more effective diagnostic and immunotherapeutic strategies for AD.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils